Isradipine Shortage: What Providers and Prescribers Need to Know in 2026

Isradipine (formerly DynaCirc, DynaCirc CR) has had a complicated supply history over the past several years. For clinicians who prescribe this dihydropyridine calcium channel blocker — particularly in pediatric hypertension or adult hypertension management — understanding the current supply situation is essential for ensuring patient continuity of care.

Current Supply Status (2026)

As of early 2026, isradipine is not listed as an active shortage by the FDA or ASHP Drug Shortages Resource Center. Teva Pharmaceuticals currently manufactures isradipine capsules in 2.5 mg and 5 mg strengths (NDC 16252-0539-01 and 16252-0540-01, 100-count bottles) and distributes through standard wholesale channels.

However, clinical teams should be aware that single-source generics carry inherent supply risk. The voluntary exit of Epic Pharma from the market in early 2023 demonstrated how quickly localized shortages can develop when only one manufacturer is active.

Shortage Timeline for Reference

• February 2023: ASHP documents isradipine capsule shortage; Epic Pharma announces discontinuation.
• 2023 (ongoing): Teva continues as the sole supplier; supply tightens at distributor and retail levels.
• December 2023: ASHP updates shortage status; Teva supply confirmed available at standard wholesale levels.
• 2024-2026: No active shortage; however, stocking gaps persist at individual pharmacies due to low volume ordering.

Clinical Considerations for Prescribing Isradipine in 2026

When initiating isradipine for new patients or managing long-term patients, consider the following:

• Pharmacy verification before prescribing. For new starts, confirm that the patient's intended pharmacy either stocks or can order isradipine promptly. This avoids a gap between prescribing and dispensing.
• Document medical necessity for isradipine specifically. If isradipine is chosen over more abundant alternatives (e.g., amlodipine) for a specific clinical reason — such as tolerability differences, pediatric dosing precision, or patient preference — document this in the chart to support continuity of care if the patient switches providers.
• Have an alternative ready. When isradipine is first prescribed, discuss with the patient which alternative medication you would recommend if isradipine becomes unavailable at their pharmacy. This prevents delayed care.

Therapeutic Alternatives for Isradipine

For adult hypertension:

• Amlodipine (Norvasc): 2.5–10 mg once daily; widely stocked; tablets and liquid available; also indicated for stable angina and CAD. Comparable antihypertensive efficacy to isradipine; may cause more peripheral edema in some patients.
• Felodipine: 2.5–10 mg once daily (ER); pharmacologically similar to isradipine (second-generation DHP CCB); direct comparison studies show similar BP control.
• Nifedipine ER: 30–90 mg once daily; inexpensive; use ER formulation only for hypertension.

For pediatric patients (off-label isradipine use):

Isradipine has been used off-label for acute hypertension in hospitalized pediatric patients (doses of 0.05–0.1 mg/kg per dose). If isradipine is unavailable, the 2017 AAP guidelines recommend ACE inhibitors, ARBs, long-acting CCBs, or thiazide diuretics as preferred initial agents for chronic hypertension in children. For acute hypertension, consult with a pediatric nephrologist or cardiologist for appropriate alternatives.

How to Help Your Patients Find Isradipine

Providers can recommend medfinder for providers as a resource to direct patients who are having difficulty locating isradipine. medfinder contacts pharmacies on the patient's behalf to find which ones have the medication in stock. Read the full provider guide: How to help your patients find isradipine in stock.

The Bottom Line

Isradipine is available in 2026, but its single-source supply structure means that prescribers should have contingency plans. Documenting the clinical rationale for isradipine, counseling patients on what to do if their pharmacy is out of stock, and having therapeutic alternatives documented in the chart will minimize care gaps for your patients.